Human Transforming Growth Factor β1

Your body is constantly repairing itself, laying down new tissue where old tissue has been damaged, dialing immune responses up or down, and deciding whether healing wounds should stop scarring or keep going. One protein sits at the center of all of these decisions: TGF-β1 (transforming growth factor beta 1). When this system works well, wounds heal cleanly and your immune system stays balanced. When it tips out of range, the consequences show up as fibrosis (excess scar tissue building up in organs like the liver, lungs, or heart), autoimmune flares, or even an environment that helps tumors hide from immune surveillance.

A blood test for TGF-β1 gives you a snapshot of how active these repair-and-remodeling signals are right now. Because TGF-β1 is involved in so many disease processes, an abnormal level rarely points to a single diagnosis on its own. Instead, it acts as a broad signal that something in your body's tissue repair or immune regulation system is off balance, and it can prompt you to look deeper with targeted follow-up testing.

What TGF-β1 Does in Your Body

TGF-β1 is the most abundant of the three TGF-β family members in humans. It is produced by platelets (the small cell fragments that help your blood clot), immune cells, and cells in virtually every organ. Most of it circulates in an inactive ("latent") form, locked inside a molecular envelope that prevents it from triggering its effects until it is needed. When tissue is damaged, mechanical forces, enzymes, or immune signals crack open that envelope and release the active form, which then binds to receptors on nearby cells.

Once active, TGF-β1 does three main things. First, it tells cells called fibroblasts to produce collagen and other structural proteins, which is how wounds heal but also how organs accumulate scar tissue if the signal does not shut off. Second, it restrains certain immune cells, particularly a subset called T regulatory cells (T-regs) that act as referees preventing your immune system from attacking your own tissues. Third, in healthy tissue it acts as a brake on cell growth, suppressing early tumor development. Paradoxically, in advanced cancers this brake often fails, and tumors can hijack TGF-β1 to shield themselves from immune attack and promote their spread to other organs.

Fibrosis: When Healing Goes Too Far

Fibrosis is essentially wound healing that never turns off. In chronic liver disease, for example, ongoing damage from hepatitis viruses, alcohol, or fatty liver disease keeps activating cells called hepatic stellate cells. TGF-β1 is the primary signal that switches these cells into collagen-producing machines. Over years, the accumulating scar tissue stiffens the liver, progressing from mild fibrosis to cirrhosis, which is the irreversible scarring that can lead to liver failure or liver cancer.

This same process plays out in the lungs (pulmonary fibrosis), the kidneys (chronic kidney disease progression), and the heart (cardiac fibrosis after heart attacks or in heart failure). In each case, TGF-β1 is a central driver. Serum levels of TGF-β1 have been proposed as a marker for tracking fibrosis severity, particularly in chronic liver disease, where higher levels correlate with more advanced stages of scarring.

Autoimmune and Inflammatory Conditions

In systemic sclerosis (scleroderma), a disease characterized by progressive skin and organ fibrosis, serum TGF-β1 levels are significantly higher than in healthy controls. A study of 56 patients with systemic sclerosis found that those with elevated levels were more likely to have lung fibrosis, digital ulcers, and more extensive skin thickening. After adjusting for age, sex, disease duration, and treatment, the association with lung fibrosis remained strong.

In lupus (systemic lupus erythematosus), the picture is more complex. A study of 284 lupus patients found that serum TGF-β1 levels averaged 3,165 pg/mL, and higher levels were associated with greater disease activity and severity. Specifically, disease features involving the eyes and cardiovascular system correlated with higher TGF-β1, while musculoskeletal involvement was associated with lower levels. The relationship between TGF-β1 and lupus is not straightforward: the protein can both suppress and fuel autoimmune responses depending on which immune cells are involved and whether T-regulatory cells are functioning normally.

Cancer Associations

Elevated serum TGF-β1 has been documented across multiple cancer types, though its role is paradoxical. In early-stage disease, TGF-β1 normally suppresses tumor growth. In advanced cancers, tumors often lose sensitivity to this growth-suppressing effect and instead use TGF-β1 to promote their own spread and shield themselves from immune attack.

In pancreatic cancer, serum TGF-β1 levels were roughly four times higher in patients with pancreatic ductal adenocarcinoma (237.6 ng/mL) compared to healthy controls (57.6 ng/mL) in a study of 146 patients. Levels distinguished malignant from benign pancreatic conditions and correlated with tumor stage and lymph node involvement. In advanced breast cancer, plasma levels were significantly elevated in patients with metastatic disease compared to healthy donors. However, in early-stage breast cancer without metastasis, serum TGF-β1 levels often do not differ from healthy controls, limiting its usefulness as an early screening tool.

Cardiovascular Risk

The relationship between TGF-β1 and heart disease is not what you might expect. While high levels drive fibrosis in the heart muscle (which is harmful), low circulating levels appear to be associated with worse cardiovascular outcomes in certain populations. A study of 155 hemodialysis patients found that those with cardiovascular disease had significantly lower TGF-β1 levels (around 26 ng/mL) compared to dialysis patients without cardiovascular disease (35 ng/mL). Each 1 ng/mL reduction in TGF-β1 was associated with a 9% increase in the risk of a cardiovascular event.

This paradox likely reflects TGF-β1's role as an anti-inflammatory agent in blood vessel walls. At normal levels, it may help protect arteries from the inflammatory processes that drive plaque buildup. When circulating levels drop too low, that protective effect is lost. In heart failure, however, plasma TGF-β1 rises significantly, roughly 3 to 4 times higher than in healthy controls, reflecting active cardiac remodeling and fibrosis.

Chronic Inflammatory Response Syndrome (CIRS)

TGF-β1 has become one of the key inflammatory markers tracked in patients with Chronic Inflammatory Response Syndrome (CIRS), a condition linked to ongoing exposure to water-damaged buildings and biotoxins such as mold. In the clinical framework developed for CIRS evaluation, elevated TGF-β1 (typically above 2,380 pg/mL) is one of three primary inflammatory markers used alongside C4a and MMP-9. The theory is that sustained biotoxin exposure drives chronic innate immune activation, leading to persistently elevated TGF-β1 that in turn disrupts T-regulatory cell function, tips the immune system toward autoimmunity, and promotes tissue remodeling in the lungs and other organs.

If you are being evaluated for CIRS or have symptoms consistent with mold-related illness (fatigue, cognitive difficulty, shortness of breath, and widespread inflammation), TGF-β1 provides a measurable marker to track whether the inflammatory cascade is active and whether treatment is bringing it under control. Levels are typically monitored before and during treatment protocols.

Reference Ranges

TGF-β1 reference ranges vary substantially between labs because the measurement is highly sensitive to how the blood sample is collected and processed. Serum values tend to be much higher than plasma values because platelets release large amounts of TGF-β1 during the clotting process. The specific test method (assay) your lab uses, whether they measure total or active TGF-β1, and how quickly the sample is processed all affect the number you receive. Always compare your results to the reference range printed on your specific lab report, and track trends within the same lab over time.

These tiers are drawn from published research and the commonly used Quest Diagnostics EDTA plasma assay (test code 91238). Your lab may use different methods and cutpoints. The range of 344 to 2,382 pg/mL reflects the double-spun plasma method, which minimizes platelet contamination. Labs using serum-based assays will report substantially higher normal ranges (some as high as 3,465 to 13,889 pg/mL) because platelets release TGF-β1 during clotting. This makes it essential to compare results only within the same lab and specimen type.

Tracking Your Trend

A single TGF-β1 reading tells you where you stand today, but the real value comes from tracking your number over time. Because TGF-β1 is influenced by so many variables, including platelet count, recent physical activity, and even how your blood was drawn, a single elevated result should always be confirmed with a repeat test before drawing conclusions.

If you are actively managing a condition where TGF-β1 is relevant (fibrotic liver disease, CIRS, autoimmune conditions, or post-treatment cancer monitoring), retest every 3 to 6 months to see whether your trend is moving in the right direction. If you are using this test as part of a general preventive screen, get a baseline reading and then retest annually. A steadily rising trend, even within the "normal" range, can signal emerging fibrotic or inflammatory activity well before it crosses a clinical threshold.

When tracking trends, always use the same lab and the same specimen type (ideally EDTA plasma rather than serum). Switching labs or specimen types can produce shifts that look like real changes but are actually just measurement artifacts.

When Results Can Be Misleading

The single biggest confounder for TGF-β1 measurement is platelet contamination of the sample. Platelets contain 40 to 100 times as much TGF-β1 as other cells, and even minor platelet activation during blood collection can artificially inflate your result. Serum-based assays are especially prone to this, because platelets release their entire TGF-β1 payload during clotting. Plasma-based assays (collected in EDTA or citrate tubes) are more reliable but still susceptible if the sample is not processed quickly or if platelets are activated during the blood draw.

Physical activity before your blood draw can also elevate TGF-β1. Studies show that even light activities of daily living (walking, climbing stairs) produce a measurable increase in plasma TGF-β1. Heavy exercise can temporarily raise levels by 30% or more. For the most accurate result, have your blood drawn after a period of rest and before any significant physical activity that day.

Platelet count itself directly affects serum TGF-β1 values. People with high platelet counts (thrombocytosis) may show falsely elevated TGF-β1, while those with low platelet counts (thrombocytopenia) will have lower values that may not reflect the true state of TGF-β1 signaling in their tissues. If your platelet count is outside the normal range, interpret your TGF-β1 result with extra caution.

Acute illness, surgery, or any condition that triggers a systemic inflammatory response can transiently raise TGF-β1. Wait at least two to four weeks after an acute illness or procedure before testing to get a reading that reflects your baseline.